Med. praxi. 2022;19(1):74-76 | DOI: 10.36290/med.2022.011

Treatment of arterial hypertension in 2022

MUDr. Alena Krajčoviechová, Ph.D.
Centrum kardiovaskulární prevence 1. lékařské fakulty UK a Fakultní Thomayerovy nemocnice, Praha

A case report of middle-aged man with grade II hypertension and moderate cardiovascular risk is presented. Combination of angiotensin-converting enzyme inhibitors and calcium channel blockers was used as initial step of the pharmacotherapy. Hypertension control was reached within 3 months. Initiation of the therapy using dual combination of antihypertensive drugs is an essential requirement for the successful treatment endorsed by guidelines, while the choice of the drugs should consider the best possible cardiovascular protection. Combination of perindopril and amlodipine, both free and fixed, is well tolerated, well adhered, and provides long-term cardiovascular protection beyond obvious blood pressure lowering effect.

Keywords: adherence, cardiovascular risk, fixed combination, guidelines, initiation of therapy.

Published: February 23, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krajčoviechová A. Treatment of arterial hypertension in 2022. Med. praxi. 2022;19(1):74-76. doi: 10.36290/med.2022.011.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. Go to original source... Go to PubMed...
    2. Widimsky J, Filipovský J, Ceral J, et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. Hypertenze & kardiovaskulární prevence. 2018;Suppl.:19.
    3. Cifkova R, Bruthans J, Wohlfahrt P, et al. 30-year trends in blood pressure, prevalence, awareness, treatment and control of hypertension in the Czech Republic. the Czech MONICA and Czech post­‑MONICA studies. PlosOne. 2019;37:e47. Go to original source...
    4. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta­‑analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300. Go to original source... Go to PubMed...
    5. Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two­‑drug fixed­‑dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018; 39(40):3654-3661. Go to original source... Go to PubMed...
    6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed­‑dose combinations of antihypertensive agents: a meta­‑analysis. Hypertension. 2010; 55(2):399-407. Go to original source... Go to PubMed...
    7. Parati G, Kjeldsen S, Coca A, et al. Adherence to Single‑Pill Versus Free‑Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta‑Analysis. Hypertension. 2021;77(2):692-705. Go to original source... Go to PubMed...
    8. Simons LA, Chung E, Ortiz M. Long‑term persistence with single‑pill, fixed‑dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Current medical research and opinion. 2017; 33(10):1783-1787. Go to original source... Go to PubMed...
    9. Verma AA, Khuu W, Tadrous M, et al. Fixed­‑dose combination antihypertensive medications, adherence, and clinical outcomes: A population­‑based retrospective cohort study. PLoS Med. 2018;15(6):e1002584. Go to original source... Go to PubMed...
    10. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. Go to original source... Go to PubMed...
    11. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre­‑diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255-323. Go to original source... Go to PubMed...
    12. Lévy BI, Mourad JJ. Renin Angiotensin blockers and cardiac protection. From basis to clinical trials. Am J Hypertens. 2021 Jul 15:hpab108. Go to original source... Go to PubMed...
    13. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin­‑converting enzyme inhibitors and angiotensin II receptor blockers on all­‑cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. JAMA Intern Med. 2014;174:773-785. Go to original source... Go to PubMed...
    14. Ferrari R. Angiotensin­‑converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert rev Cardiovasc Ther. 2005;3:15-29. Go to original source... Go to PubMed...
    15. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study; PERTINENT. Cardiovasc Res. 2007; 73:237-246. Go to original source... Go to PubMed...
    16. Bertrand ME, Ferrari R, Remme WJ, et al. Clinical synergy of perindopril and calcium‑channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010;159(5):795-802. Go to original source... Go to PubMed...
    17. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipin adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. Go to original source... Go to PubMed...
    18. Gupta A, Mackay J, Whitehouse a, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153):1127-1137. Go to original source... Go to PubMed...
    19. Gupta A, Whiteley W, Godec T, et al. Long term benefits of blood pressure treatment on the incidence of atrial fibrillation, heart failure and cardiovascular morbidity and mortality: 20-years follow-up of ASCOT-LEGACY. J Hypertens. 2021;39:e8. Go to original source...
    20. Hatala R, Pella D, Hatalová K, et al. Optimization of blood pressure treatment with fixed-combination perindopril/amlodipine in patients with arterial hypertensio. Clin Drug Investig. 2012; 32(9):603-612. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.